China May Bridge-Study Pfizer's COVID-19 Vaccine Candidate

Fosun Pharmaceutical Group's Chief Medical Officer Hui Aimin told Reuters in an interview on November 3, 2020, 'they would seek emergency use authorization in China for the phase 3 BNT162b2 vaccine candidate, which is being produced by Pfizer and BioNTech.

Hui indicated Fosun was applying for a 'bridge study' for the BNT162b2 vaccine candidate, designed to evaluate whether the large trial data gathered, overseas could be extrapolated to the populace of China.'